Personal Genome Diagnostics Announces Collaboration to Develop Plasma-Based Companion Diagnostic for Five Prime Therapeutics' Targeted Immuno-Oncology Drug Candidate Bemarituzumab

Author's Avatar
Apr 03, 2018
Article's Main Image

--PGDx's Non-Invasive Liquid Biopsy Assay Is Intended to Identify Cancer Patients Most Likely to Benefit from Treatment with Bemarituzumab (FPA144) --

PR Newswire